비교리스트

 카트 문의
시장보고서
상품코드
1632574

임상시험 관리 서비스 시장 규모, 점유율, 동향분석 보고서 : 서비스별, 적응증별, 최종용도별, 지역별, 부문 예측(2025-2030년)

Clinical Trial Management Services Market Size, Share & Trends Analysis Report By Services, By Indication, By End Use, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 145 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

임상시험 관리 서비스 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 전 세계 임상시험 관리 서비스 시장 규모는 2030년까지 538억 5,000만 달러에 달할 것으로 예측됩니다.

이 시장은 2025년부터 2030년에 걸쳐 CAGR 8.26%로 확대될 전망입니다. 임상시험 활동의 아웃소싱 경향이 높아지고, 첨단치료의 연구개발의 활성화, 임상시험의 세계화 등이 시장의 성장을 가속하는 주요 요인이 되고 있습니다.

임상시험 건수는 지난 20년간 크게 증가하고 있습니다. 그 배경에는 효율성을 향상시킨 신규 의약품에 대한 요구 증가와 최첨단 의료 기술의 침투가 있습니다. Clinical trials.gov에 따르면, 2020년의 총 시험 수는 32만 5,773건이었지만, 2022년 4월 기준 총 시험 수는 41만 903건을 넘었습니다.

임상 모니터링, 데이터 관리, 시설 모니터링, 의료 조명 서비스 등의 임상시험 관리 서비스는 비용 효율적이며 시간을 절약할 수 있습니다. 이들은 또한 시설 간 임상 데이터의 조화와 실패율의 감소로 이어집니다. 게다가 클라우드 컴퓨팅, 인공지능(AI), 빅데이터 처방, 예측 분석, 의료용 IoT, 모바일 기술 등 디지털 기술의 통합은 여전히 큰 발전에 있습니다. 이러한 기술은 시험의 속도를 가속화하면서 생산성을 향상시키는 데 큰 잠재력을 보여줍니다.

COVID-19의 유행은 시장에 큰 영향을 주었고, 시험 실시에 대한 대안에 대한 예기치 않은 긴급성을 창출하고, 현장 모니터링 방문을 제한했습니다. COVID-19 감염의 확대를 억제하고 동시에 임상 연구를 수행하기 위해 연구자들은 원격 시험 모니터링 서비스와 플랫폼을 이용하게 되었습니다. 예를 들어, 2020년 플로렌스 조사에 따르면 60% 이상의 임상시험 시설과 임상응답자가 임상연구를 위한 원격 사이트 모니터링 솔루션을 50% 이상 수용하고 있다고 말했습니다.

임상시험 관리 서비스 시장 : 분석 개요

  • 임상시험 모니터링 분야는 2024년 임상시험 관리 서비스 산업을 지배했습니다.
  • 2024년에 임상시험 관리 서비스 업계를 지배한 것은 종양학 분야였습니다. 암 연구개발 투자 증가, 암 이환율 증가, 개별화된 약물요법에 대한 수요 증가에 더해, 암 분야에 있어서의 혁신적인 개발이 급증하고 있는 것이 성장의 주된 요인이 되고 있습니다.
  • 2024년 임상시험 관리 서비스 산업은 의약품 부문이 지배적이었습니다. 이는 지난 20년간 R&D 투자 증가와 신약 개발에 크게 기여했습니다.
  • 북미가 임상시험 관리 서비스 시장을 독점했습니다. 신치료법이나 신약 수요에 의해 이 지역 전체에서 임상시험이 급증했습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 임성시험 관리 서비스 시장 : 변동 요인·경향·범위

  • 시장 연관 전망
    • 상위 시장 전망
    • 부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 임상시험 관리 서비스 시장 : 분석 도구
    • Porter's Five Forces 분석
    • PESTEL 분석
    • COVID-19의 영향 분석

제4장 임상시험 관리 서비스 시장 : 서비스별 추정·동향 분석

  • 부문 대시보드
  • 세계의 임상시험 관리 서비스 시장 : 변동 분석, 서비스별
  • 세계의 임상시험 관리 서비스 시장 규모와 동향 분석, 서비스별(2018-2030년)
  • 시험 모니터링
  • 규제 당국에 제출
  • 시험 데이터 관리
  • 메디컬 라이팅
  • 사이트 관리
  • 프로젝트 관리
  • 기타

제5장 임상시험 관리 서비스 시장 : 적응증별 추정·동향 분석

  • 부문 대시보드
  • 세계의 임상시험 관리 서비스 시장 : 변동 분석, 적응증별
  • 세계의 임상시험 관리 서비스 시장 규모와 동향 분석, 적응증별(2018-2030년)
  • 자가면역/염증
  • 통증 관리
  • 종양학
  • 중추 신경계 질환
  • 당뇨병
  • 비만
  • 심장혈관
  • 기타

제6장 임상시험 관리 서비스 시장 : 최종 용도별 추정·동향 분석

  • 부문 대시보드
  • 세계의 임상시험 관리 서비스 시장 : 변동 분석, 최종 용도별
  • 세계의 임상시험 관리 서비스 시장 규모와 동향 분석, 최종 용도별(2018-2030년)
  • 제약
  • 바이오의약품
  • 의료기기

제7장 임상시험 관리 서비스 시장 : 지역별 추정·동향 분석

  • 지역별 시장 대시보드
  • 세계 시장 현황 : 지역별
  • 시장 규모의 예측·동향 분석(2018-2030년)
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제8장 경쟁 구도

  • 시장 진출기업의 분류
    • 시장 리더
    • 신흥기업
  • 기업 시장 포지션 분석
  • 기업 프로파일
    • CTI Clinical Trial &Consulting
    • Charles River Laboratories
    • Medpace Holdings, Inc.
    • Wuxi Apptec
    • SGS Societe Generale de Surveillance SA
    • Laboratory Corporation of America Holdings
    • IQVIA, Inc.
    • Syneous Health
    • Atlantic Research Group
    • ICON Plc
KTH 25.02.28

Clinical Trial Management Services Market Growth & Trends:

The global clinical trial management services market size is anticipated to reach USD 53.85 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.26% from 2025 to 2030. The increasing trend of outsourcing clinical trial activities, the rise in research and development of advanced therapies, and the globalization of clinical trials are a few key factors driving the growth of the market.

The number of clinical trials has significantly increased in the past two decades. This is due to the rising need for novel pharmaceutical products with improved efficacy as well as the increasing penetration of cutting-edge medical technologies. According to Clinical trials.gov, the total number of clinical trials accounted for 325,773 in 2020, whereas, as of April 2022, the number of clinical trials this year totaled more than 410,903.

Clinical trial management services such as clinical monitoring, data management, site monitoring, and medical writing service are cost-effective and time-saving. These also harmonize clinical data across sites and failure rates. Furthermore, the integration of digital technologies, including cloud computing, Artificial Intelligence (AI), big data prescriptive, and predictive analytics, the Internet of Medical Things, and mobile technology remain major developments on the horizon. These technologies have shown great promise in improving productivity while accelerating the pace of clinical trials.

The COVID-19 pandemic significantly impacted the market. It created an unexpected urgency for alternative solutions to clinical trial execution, limiting on-site monitoring visits. It prompted researchers to use remote clinical trial monitoring services and platforms to reduce the spread of the COVID-19 infection as well as to simultaneously function in clinical research. For instance, according to the Florence survey in 2020, more than 60% of clinical study sites and clinical trial sponsors stated more than 50% acceptance of remote site monitoring solutions for clinical research.

Clinical Trial Management Services Market Report Highlights:

  • The clinical trial monitoring segment dominated the clinical trial management services industry in 2024.
  • The oncology segment dominated the clinical trial management services industry in 2024. The rise in oncology R&D investments, the increasing cancer incidences, and the growing demand for personalized medications, coupled with a surge in innovative developments in the field of oncology, are the key factors driving the growth.
  • The pharmaceuticals segment dominated the clinical trial management services industry in 2024. This can be largely attributed to the rise in R&D investments and the development of new drugs over the past two decades.
  • North America dominated the clinical trial management services market. The demand for new therapies and drugs has led to a surge in clinical trials across the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Clinical Trial Management Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing technological advancement in the clinical trial monitoring services
      • 3.2.1.2. Rise in R&D expenditure by pharmaceutical and biopharmaceutical companies
      • 3.2.1.3. Growth in the number of outsourced projects related to clinical trial management services
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost associated with clinical trial management services
      • 3.2.2.2. Stringent regulatory policies for clinical trial management services
  • 3.3. Clinical Trial Management Services Market: Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Clinical Trial Management Services Market: Services Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Clinical Trial Management Services Market, Services Movement Analysis
  • 4.3. Global Clinical Trial Management Services Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
  • 4.4. Clinical Trial Monitoring
    • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. Regulatory Submissions
    • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.6. Clinical Trial Data Management
    • 4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.7. Medical Writing
    • 4.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.8. Site Management
    • 4.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.9. Project Management
    • 4.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Clinical Trial Management Services Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Clinical Trial Management Services Market, Indication Movement Analysis
  • 5.3. Global Clinical Trial Management Services Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Autoimmune/Inflammation
    • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Pain Management
    • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.7. CNS Conditions
    • 5.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.8. Diabetes
    • 5.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.9. Obesity
    • 5.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.10. Cardiovascular
    • 5.10.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Clinical Trial Management Services Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Clinical Trial Management Services Market, End Use Movement Analysis
  • 6.3. Global Clinical Trial Management Services Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceuticals
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Biopharmaceuticals
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. Medical Devices
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Clinical Trial Management Services Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Scenario
      • 7.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Position Analysis
  • 8.3. Company Profiles
    • 8.3.1. CTI Clinical Trial & Consulting
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Charles River Laboratories
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Medpace Holdings, Inc.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Wuxi Apptec
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. SGS Societe Generale de Surveillance SA
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Laboratory Corporation of America Holdings
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. IQVIA, Inc.
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Syneous Health
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Atlantic Research Group
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. ICON Plc
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제